SHSE:600062's PB Ratio is ranked better than 62.79% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs SHSE:600062: 1.41
During the past 12 months, China Resources Double-Crane Pharmaceutical Co's average Book Value Per Share Growth Rate was 11.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of China Resources Double-Crane Pharmaceutical Co was 83.20% per year. The lowest was -1.50% per year. And the median was 10.20% per year.
Back to Basics: PB Ratio
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
China Resources Double-Crane Pharmaceutical Co PB Ratio Related Terms
China Resources Double-Crane Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co PB Ratio Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
China Resources Double-Crane Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a PB Ratio of 1.41 as of Jul. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is 21% below median its historical median of 1.78. Over the past decade, China Resources Double-Crane Pharmaceutical Co's PB Ratio has ranged from 1.21 to 3.55. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #342 out of 919 companies in the Drug Manufacturers industry, placing it in the top 37.2%.
Is China Resources Double-Crane Pharmaceutical Co's PB Ratio too high?
China Resources Double-Crane Pharmaceutical Co's current PB Ratio of 1.41 is 21% below median its 10-year median of 1.78. Over the past 10 years, this metric has ranged from a low of 1.21 to a high of 3.55. The Drug Manufacturers industry median PB Ratio is 1.91. China Resources Double-Crane Pharmaceutical Co's value of 1.41 is 26.2% below this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #342 out of 919 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #342 out of 919 companies for PB Ratio. This puts China Resources Double-Crane Pharmaceutical Co in the upper half of its industry. The industry median PB Ratio is 1.91. China Resources Double-Crane Pharmaceutical Co's value of 1.41 is 26.2% below this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own PB Ratio has ranged from 1.21 to 3.55 over the past decade. While the company's 10-year median is 1.78 vs. the industry median of 1.91, China Resources Double-Crane Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current PB Ratio of 1.41 is 26.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current PB Ratio is 1.41, which is 21% below median its own 10-year median of 1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.75, compared to a current price of ¥16.43 — trading 12.4% below its estimated fair value. The current PB Ratio is 1.41, which is 21% below median its 10-year median of 1.78 and 26.2% below the Drug Manufacturers industry median of 1.91. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current PB Ratio is 1.41 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
PB Ratio: 1.41 (21% below median its 10-year median of 1.78)
GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
Industry Position: 26.2% below the Drug Manufacturers median (#342 of 919)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Business Description
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score
Get the complete analysis for SHSE:600062
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
